Will Maddox is a Managing Editor at D Magazine. He covers a range of topics including medicine and healthcare, healthcare technology, and the intersection of business and sports, with a focus on patient care, digital health, and entrepreneurship. His work has been featured in D Magazine and Biotech.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Will Maddox's coverage is heavily focused on healthcare and pharmaceutical industries, with a significant emphasis on press releases and private sector announcements. He also covers topics related to business, industry, health, and wellbeing.
Given the focus on press releases and private sector announcements in the healthcare industry, Will would likely be interested in receiving pitches from PR representatives of companies within this sector announcing major developments or initiatives. Additionally, he may be receptive to pitches that offer data-driven insights into trends within these industries.
As there is no specified geographic focus for Will's coverage, it is important to note that his articles cover both national and international news related to healthcare and business but are mainly centered around North Texas.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.
By: Will Maddox
Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own record-breaker this week.
Six weeks after Intellia Therapeutics reported that it met its
Nature Index's latest research rankings show that China continues to be the clear leader in contributions to scientific journals, with a 22% increase between 2024 and 2025.
By: Will Maddox
From persevering with a tricky Alzheimer's program to securing a late-stage CD38-directed antibody and posting encouraging lupus data , Biogen has remained in the news recently—and that's no accident.
AI drug design specialist Protillion Biosciences has inked a $510 million biobucks collaboration and license agreement with Merck & Co. that brings together Protillion's platform and Merck's drug discovery expertise.
By: Will Maddox
Jazz Pharmaceuticals is looking to bolster its oncology research bona fides via a partnership with AbCellera to discover and develop
By: Will Maddox
Vedana Therapeutics has emerged from stealth with $46 million in series A financing aimed at advancing the company's subcutaneously delivered antibodies for migraine prevention.
After years of antifungal resistance increasingly making standard-of-care treatments less effective, F2G and Shionogi have released phase 3 data
By: Will Maddox
For Bionyra Pharma co-founder and CEO Frédéric Marrache, M.D., Ph.D., “the planets had to align” to pull him out of his R&D VP role at Sanofi.
